Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  FibroGen Inc    FGEN

FIBROGEN INC (FGEN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/13/2018 07/16/2018 07/17/2018 07/18/2018 07/19/2018 Date
63.9(c) 63.05(c) 65.7(c) 65.15(c) 64.4(c) Last
578 657 594 521 375 827 385 976 462 019 Volume
-2.22% -1.33% +4.20% -0.84% -1.15% Change
More quotes
Financials (USD)
Sales 2018 182 M
EBIT 2018 -138 M
Net income 2018 -209 M
Finance 2018 668 M
Yield 2018 -
Sales 2019 334 M
EBIT 2019 -30,6 M
Net income 2019 -80,1 M
Finance 2019 696 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 26,5x
EV / Sales2019 14,3x
Capitalization 5 487 M
More Financials
Company
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics to treat unmet medical needs.It focuses on fibrosis and hypoxia-induced factor biology to generate programs targeting therapeutic areas.The company was founded by Thomas B. Neff on September 29, 1993 and is... 
More about the company
Surperformance© ratings of FibroGen Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FIBROGEN INC
07/10Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks
AC
06/29FIBROGEN : Anemia specialist Akebia merges with Keryx on the eve of a blockbuste..
AQ
06/29Akebia, Keryx to merge, creating kidney disease specialist ahead of showdown ..
AQ
06/11FIBROGEN INC : Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clini..
AC
06/11FIBROGEN, INC. (NASDAQ : FGEN) Files An 8-K Regulation FD Disclosure
AQ
06/08FIBROGEN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
06/08FIBROGEN : Announces Completion of Enrollment in U.S. Phase 3 Clinical Program f..
AQ
06/07FIBROGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/07FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program ..
GL
06/06FIBROGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/12Want automatic email alerts for $AMBR $FGEN $EPAM $GRPN $INGN? Subscribe to M.. 
07/12Zacks Investment Research Upgrades FibroGen $FGEN to “Hold”  
07/10$28.70 Million in Sales Expected for FibroGen Inc $FGEN This Quarter  
07/09FibroGen $FGEN Hits New 52-Week High at $68.55  
07/05$CNAT $FGEN $GLPG $TPIV $BMY $GALT $GILD $LJPC $MRK  
More tweets
Qtime:48
News from SeekingAlpha
07/10SECOND HALF OUTLOOK : What Now After Strong Double-Digit Gains? 
07/05Galectin Therapeutics IPF Patent Solidifies Platform Technology Status 
06/30STOCKS TO WATCH : Tariffs Don't Take Holidays 
06/19Tricida Prepares For $175 Million U.S. IPO 
06/16A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals 
Chart FIBROGEN INC
Duration : Period :
FibroGen Inc Technical Analysis Chart | FGEN | US31572Q8087 | 4-Traders
Technical analysis trends FIBROGEN INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 71,6 $
Spread / Average Target 9,9%
EPS Revisions
Managers
NameTitle
Thomas Byron Neff Chairman & Chief Executive Officer
Pat Cotroneo Chief Financial Officer & Vice President-Finance
Kin Hung Yu Chief Medical Officer
Jorma Tapio Routti Independent Director
Kalevi Kurkijärvi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FIBROGEN INC35.87%5 487
CELLTRION, INC.--.--%32 830
IQVIA HOLDINGS INC12.03%22 488
LONZA GROUP9.31%21 400
INCYTE CORPORATION-25.70%14 887
SEATTLE GENETICS, INC.27.16%10 750